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Lipworth, Dr C.M. Jackson and
Prof. H. Chrystyn re: paper by
Milanowski et al. (Respir Med 1999; 93:
245±251)We would like to thank Dr Lipworth and Prof. Chrystyn
for their interest and comments, which point to a number of
important issues in the design of inhaled corticosteroid
trials and their application to asthma treatment. They are
quite correct in pointing to the diculty of demonstrating
relative potency of inhaled corticosteroids at high doses and
the importance of assessing equivalence also at low doses.Indeed, the focus of the high dose study (2000mg day71)
was primarily on demonstrating comparable safety and
tolerability of BDP-HFA and BDP-CFC, while the lower
dose study was designed to evaluate ecacy and safety in
patients not currently maintained on inhaled steroids. This
showed significant and equivalent improvement in lung
function and asthma symptoms with both treatments,
Moreover, the lung function responses seen in the
Milanowski et al., studies are in keeping with responses
seen in other published studies of high dose inhaled
corticosteroids (1,2). We would dispute the point by
Chrystyn concerning the studies being under-powered to
provide evidence of equivalence since both were planned
with full statistical considerations in determining detection
of any clinically relevant dierences between the hydro-
fluoroalkane (HFA) and chlorofluorocarbon (CFC) pro-
ducts.
The issue of assessing ecacy at low doses has in fact
already been addressed in another 12 week study in 200
asthmatic children with a beclomethasone dipropionate
(BDP) dose of 100 mg b.d., using similar formulations of
CFC and CFC-free BDP to those used in the adult
asthmatic study by Milanowski et al., 1999. This paediatric
study has also shown significant mean improvements in
PEF for both BDP-CFC and BDP-HFA that were within
3% of each other at endpoint (95% Cl 991, 1062%), with
similar equivalence in other ecacy and tolerability
parameters. It is intended that these data be published in
due course.
Thus therapeutic equivalence of these BDP-HFA and
BDP-CFC formulations (Norton Healthcare Ltd, U.K.)
has now been demonstrated across a wide dose range in
patients with all severities of asthma.
The pharmacokinetic data of Lipworth and Jackson and
the hypothetical lung deposition referred to by Chrystyn,
although interesting, are not necessarily reflected in clinical
practice in terms of asthma control. Caution must be
exercised when interpreting systemic steroid absorption
from both swallowed and inhaled drug. It is not stated
whether their data were acquired from healthy volunteers
or patients with asthma, but it is likely that the ratios of
plasma beclomethasone-17 monopropionate from inhaled
BDP-CFC and BDP-HFA will vary between subjects and
also across doses, as well as with inhaler technique. Taking
an arbitrary mean dose ratio from pharmacokinetic data
based on systemic absorption and then switching patients
to a lower inhaled dose of BDP-HFA when changing from
BDP-CFC exposes some patients to a risk of under-
treatment and possible asthma exacerbation. Based on the
evidence from our own studies, where the aim was to
evaluate therapeutic equivalence, it is not only justified, but
would appear far simpler and less risky, as well as being
more convenient for asthma suerers and health profes-
sionals, to switch patients on a 1:1 basis when changing
from BDP-CFC to BDP-HFA. Doses can later be titrated
down on an individual basis in a manner consistent with
good current practice (e.g. BTS guidelines). As to the
potential for the HFA product to result in a less favourable
safety profile, this has not been the case with BDP-HFA in
these studies nor in the post-marketing experience with this
180 LETTERS TO THE EDITORproduct in Ireland. Following its launch in February 1998,
we estimate in excess of 10000 patient years experience has
been gained without any untoward experiences being
reported. This represents the greatest cumulative experience
obtained to date for any BDP-HFA product and is
arguably the strongest and most meaningful evaluation of
such a product.
V. L. PERRIN AND D. W. FAKES
Norton Healthcare Ltd.,
London, U.K.
References
1. Molema J, Lammers J-WJ, van Herwaarden CLA,
Folgering H Th M. Eects of inhaled beclomethasone
dipropionate on beta2-receptor function in the airways
and adrenal responsiveness in bronchial asthma. Eur J
Clin Pharmacol 1988; 34: 577–583.
2. Dahl R, Ringdal N, Ward SM, Stampone P, Donnell D.
Equivalence of asthma control with new CFC-free
formulation HFA-134a beclomethasone dipropionate
and CFC-beclomethasone dipropionate, Br J Clin Pract
1997; 51: 11–15.Re: inhaled beclomethasone (BDP)
with non-CFC propellent (HFA 134a)
is equivalent to BDP-CFC for the
treatment of asthma (Respir Med 1999;
93:245±251)In this journal Milanowski and co-workers published their
results of an equivalence trial comparing a HFA- and CFC-
BDP formulation (1). Their intention was to show that the
recently developed HFA-formulation is equivalent to the
older CFC one. The conclusion was that both formulations
were equivalent and a ‘change-over of patients straight-
forward’. A number of reasons render this conclusion of
equivalence, however, questionable.
This study based the equivalence claim on reporting a
lack of statistically significant dierences between two
preparations. This approach has become known as the so-
called power approach. In this approach, a priori, one
defines a maximal allowable dierence between the two
preparations. Subsequently one calculates a sample size
enabling the researcher to find that dierence. When the
study evaluation does not report any significant dierences,
the actual dierence between the two preparations must
have been smaller than the predefined critical (and
detectable) one. The conclusion therefore is that the actual
dierence between the two is smaller that the critical one
and equivalence can be claimed. However, the sample size
calculation (which is pivotal) is always based on retro-
spective data (mean and standard deviation), while thesedata can dier from the actual in the selective sample. So it
is possible that the standard deviation in the sample is
larger than in the retrospective data. When that happens,
the study will by definition result in no significant
dierences: the study is under-powered due to the larger
standard deviation (2).
When we follow this approach based on the data of the
low dose study in Table 3 of the publication, we can read
a mean FEV1 of 25+08 l for the reference CFC-BDP
formulation. So with an acceptable dierence of 02 l, the
lowest test HFA-BDP may be 23 l. Sample size calculation
with a standard deviation of 08 gives us a size per group of
338. A standard deviation of 0305, together with the other
data, would lead to the cited sample size of 50 per group.
We therefore ask ourselves whether this study was under-
powered and could not but result in non-significant
dierences, due to an incorrect estimate of the standard
deviation.
The power approach was put out of use much for the
above reason. The current approach of the two one-sided t-
test does not suer from the drawback of under-powered
studies. It is designed in such a way that an under-powered
study always leads to a conclusion of inequivalence. This
approach is based on a null hypothesis of inequivalence and
an alternative one of equivalence. To claim equivalence one
must reject inequivalence, which in statistical terms means
‘significant dierences’. It is easy to see that under-powered
study will never be able to reject the null hypothesis of
inequivalence. A study must be suciently large to reject
inequivalence and accept equivalence. In this way it is
impossible to market inequivalent preparations as result of
a flawed power approach study. The patient risk to use
inequivalent product is significantly reduced after imple-
mentation of the two one-sided t-test.
Now following the two one sided t-test approach and
again assuming that the maximal allowable dierence is 02
l, the dierence between the two preparations is 01 l with a
standard deviation of 0.8, the sample size per group would
be 1097!
The next point is the choice of a FEV1 dierence of 02 l
as the maximal allowable dierence. The authors thereby
state that the mean FEV1 in the HFA-group could be
25702=23 l and still be acceptable. A value lower than
23 l however would mean that the improvement in that
group would be very low: an increase from 22 to 23 l
would be sucient to claim non-significant dierences. In
other words, while the CFC-group improved 03, an
improvement of a mere 01 l in the HFA-group would be
sucient to claim equivalence. We feel that such a large
dierence between the improvements is not acceptable.
To conclude we feel that the approach taken by the
authors does not allow the conclusion of equivalence and
would ask them to elaborate on the starting points of their
sample size calculations.
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